Why the study?
Diabetes significantly increases CVD risk, but the efficacy of low-dose aspirin for prevention in this population remains debated.
Does low-dose aspirin reduce the incidence of major adverse cardiovascular events in high-risk type 2 diabetic patients?
Population
100 type 2 diabetic patients without previous CVD
Comparison
Aspirin 81 mg/day vs placebo
Design
Double-blind, placebo-controlled, randomized trial
Follow-up
One year
Key result
Low-dose aspirin did not significantly reduce the incidence of major adverse cardiovascular events compared to placebo in high-risk patients with type 2 diabetes (HR 0.44, p=0.23).
Authors
Loading...
May support aspirin for primary CVD prevention in T2D without prior events; extends small-trial data but leaves net benefit open.
RCT (n=100)
Double-blind
Randomized
No
Does low-dose aspirin reduce the incidence of major adverse cardiovascular events in high-risk type 2 diabetic patients?
Hazard Ratio: 0.44 (95% CI 0.13–1.45)
Absolute Event Rate: 4% vs 10%
p-value: p=0.23
In high-risk type 2 diabetic patients, low-dose aspirin did not significantly reduce overall MACE at one year, though subgroup analysis suggested potential benefit for those with prior cardiovascular illness.
Jilani et al. (2025) conducted an RCT in Type 2 diabetes at high risk for cardiovascular disease (n=100). Low-dose aspirin vs. Placebo was evaluated on Incidence of major adverse cardiovascular events (MACE) (HR 0.44, 95% CI 0.13-1.45, p=0.23). Low-dose aspirin did not significantly reduce the incidence of major adverse cardiovascular events compared to placebo in high-risk patients with type 2 diabetes (HR 0.44, p=0.23).